Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Vertex Pharmaceuticals is diversifying beyond its core cystic fibrosis business through its $10 billion acquisition of Crinetics Pharmaceuticals. The company now has Palsonify (approved for acromegaly) and Atumelnant (in development for rare hormonal disorders) with estimated peak revenue potential exceeding $5 billion. Combined with other pipeline candidates like povetacicept and gene-editing medicine Casgevy, Vertex's hormone disorder franchise could become a significant growth driver over the medium term.